Lindbrook Capital LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Lindbrook Capital LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 37.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,269 shares of the biopharmaceutical company’s stock after purchasing an additional 883 shares during the quarter. Lindbrook Capital LLC’s holdings in Gilead Sciences were worth $265,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Morgan Stanley grew its position in shares of Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after acquiring an additional 158,794 shares during the period. Northern Trust Corp raised its position in shares of Gilead Sciences by 3.5% during the 3rd quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after buying an additional 504,475 shares during the period. Pacer Advisors Inc. increased its holdings in Gilead Sciences by 10.8% in the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock valued at $408,829,000 after purchasing an additional 493,920 shares during the last quarter. AQR Capital Management LLC increased its holdings in Gilead Sciences by 12.5% in the 3rd quarter. AQR Capital Management LLC now owns 4,773,688 shares of the biopharmaceutical company’s stock valued at $357,740,000 after purchasing an additional 531,314 shares during the last quarter. Finally, Clearbridge Investments LLC increased its holdings in Gilead Sciences by 179.0% in the 3rd quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock valued at $340,526,000 after purchasing an additional 2,915,141 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Cantor Fitzgerald lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Mizuho decreased their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Finally, Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $84.71.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.3 %

Shares of GILD opened at $66.95 on Tuesday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The firm has a 50 day simple moving average of $71.81 and a 200-day simple moving average of $76.51. Gilead Sciences, Inc. has a 1-year low of $65.90 and a 1-year high of $87.86. The stock has a market cap of $83.36 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same period last year, the business earned $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were paid a $0.77 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.60%. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is presently 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.